Immuno-Oncology Drug Market to Surpass USD 40 Million Mark in Next 10 Years, Predicts MP Advisors in Its Report Available at

11 May 2016 • by Natalie Aster

LONDON – Top pharma players keep on improving their production by applying different approaches such as concentrating on selected markets and therapy areas, M&As, consolidation in animal health and vaccines business, and more.

The oncology segment was one of major areas of interest for large-caps in 2014-2015. At present, the immuno-oncology represents one of the most explosive fields within the biotechnology space. Bristol-Myers, Roche and Merck are some of leaders in this marketplace.

The immuno-oncology drug market is expected to surpass the USD 40 billion mark over the next decade. Anti-Infective is still a big attraction for big pharm.

Meanwhile, pharma companies continue developing biosimilars, and many of them are currently in the latest stage of clinical trials.

Insightful research report “Large CAP Pharma US & EU Outlook 2016: Maximizing Their Strength on Fewer Therapy Class, Personalized Medicine, Novel Target and Biosimilars for Future Growth” drawn up by MP Advisors offers a comprehensive discussion of the global biopharmaceutical market. The study sheds light on individual large-cap companies, sheds light on promising drug candidates being in their late stage pipelines.

It analyzes the competitive environment in detail and looks at important therapy areas. Valuable data on major marketed drugs and impact several important upcoming milestones are expected to have on the industry are contained in the report, too.

Other Markets Covered by the Publisher Comprise:

More topical research reports by our partner are available at MP Advisors page


The Market Publishers, Ltd.
Natalie Aster
Tel: +44 208 144 6009
Fax: +44 207 900 3970